Xconomy Forum: New England’s Emerging Biotech Stars

The New England biotech hub has been on a roll the past couple years, with the breakout success of Vertex Pharmaceuticals, the ongoing revival at Biogen Idec, Sanofi's $20 billion acquisition of Genzyme, and the continuing concentration of Big Pharma R&D in Boston. But both the science and business of biotech move fast. So which companies, and which entrepreneurs, are the ones to watch for the next five to 10 years? We'll have keynotes from two of Boston's biotech leaders. We'll hear from the CEOs of five biotech startups that are gaining traction in the industry. And we'll have an interactive panel discussion about an important but sometimes overlooked source of startup funding: grants from non-profit disease foundations. Join us for this extraordinary gathering of up-and-comers in the New England biotech hub.
Keynote speakers: George Scangos, CEO, Biogen Idec Mark Levin, Partner, Third Rock Ventures
Featured Speakers: Chip Clark, CEO, Genocea Doug Fambrough, CEO, Dicerna Tillman Gerngross, CEO, Adimab Joanna Horobin, CEO, Syndax Joseph Yanchik, CEO, Aileron Louise Perkins, Chief Scientific Officer, Multiple Myeloma Research Foundation Julia L. Greenstein, Assistant Vice President, Cure Therapies, Juvenile Diabetes Research Foundation Rick Winneker, SVP, Leukemia & Lymphoma Society Michael Kauffman, CEO, Karyopharm Jens Eckstein, President, SR One Doug Williams, Executive Vice President, Research and Development, Biogen Idec Tuan Ha-Ngoc, CEO, Aveo Pharmaceuticals
Full Agenda here.
Schedule: Registration: 12:30 – 1:3 0 pm Program: